{"id":506104,"date":"2020-09-09T16:50:01","date_gmt":"2020-09-09T16:50:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=506104"},"modified":"2020-09-09T16:50:01","modified_gmt":"2020-09-09T16:50:01","slug":"acromegaly-global-api-manufacturers-marketed-and-phase-iii-drugs-landscape-2020-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/acromegaly-global-api-manufacturers-marketed-and-phase-iii-drugs-landscape-2020-by-delveinsight_506104.html","title":{"rendered":"Acromegaly Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020 by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1599625473.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Acromegaly Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020 by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1599625473.jpeg\" alt=\"Acromegaly Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020 by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">&#8220;Acromegaly &#8211; Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020&#8221; report by DelveInsight offers comprehensive insights on marketed and Phase III products for Acromegaly. The marketed products information covers their product details, patents (US &#038; EU), historical and forecasted sales till 2023. <\/div>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&#8220;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/acromegaly-global-api-manufacturers-marketed-and-phase-iii-drugs-landscape\" target=\"_blank\"><strong>Acromegaly &#8211; Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020<\/strong><\/a>&#8221; report by&nbsp;<span data-mce-mark=\"1\">DelveInsight<\/span>&nbsp;offers comprehensive insights on marketed and Phase III products for Acromegaly. The marketed products information covers their product details, patents (US &amp; EU), historical and forecasted sales till 2023. It further provides the marketed products API manufacturer details for United States, Europe, China, and India. The report also covers the emerging Phase III pipeline assets for Acromegaly including their detailed product profiles.<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">Additionally, the report also highlights the future competitive landscape for Acromegaly therapeutics. Depending on information availability comprehensive coverage of the following for Acromegaly marketed products for Acromegaly descriptive marketed product profiles for Acromegaly including (but not limited to) drug description, regulatory milestones, product development and R&amp;D activities encompassing clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Also provided are the historical and forecasted global sales till 2023 for each product.<\/p>\n<p style=\"text-align: justify;\">Global API Manufacturers of marketed products for Acromegaly coverage of API manufacturers for&nbsp;<span data-mce-mark=\"1\">Acromegaly<\/span><span data-mce-mark=\"1\">&nbsp;marketed products spanning across United States, Europe, China and India. The manufacturers details include manufacturers name along with their location Emerging Phase III products for Acromegaly descriptive Phase III product profiles for Acromegaly including (but not limited to) drug description, product development and R&amp;D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Also their forecasted global sales are provided till 2023.<\/span><\/p>\n<p style=\"text-align: justify;\"><strong>View full report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/acromegaly-global-api-manufacturers-marketed-and-phase-iii-drugs-landscape\" target=\"_blank\">https:\/\/www.delveinsight.com\/report-store\/acromegaly-global-api-manufacturers-marketed-and-phase-iii-drugs-landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Report Methodology&nbsp;<\/strong><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\"><span data-mce-mark=\"1\">The report provides insights into:&nbsp;<\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li class=\"ql-align-justify\"><span data-mce-mark=\"1\">Detailed description of the indication including causes, symptoms, pathophysiology, diagnosis and treatment<\/span><\/li>\n<li class=\"ql-align-justify\"><span data-mce-mark=\"1\">Comparative analysis of the marketed and emerging products&nbsp;<\/span><\/li>\n<li class=\"ql-align-justify\"><span data-mce-mark=\"1\">Detailed profiles for the marketed therapies available including mechanism of action, dosage and administration regulatory milestones, other development activities&nbsp;<\/span><\/li>\n<li class=\"ql-align-justify\"><span data-mce-mark=\"1\">Global sales of the marketed therapies from 2012-2023 is covered in the report<\/span><\/li>\n<li class=\"ql-align-justify\"><span data-mce-mark=\"1\">Global API Manufacturers for marketed therapies are provided across United States, Europe, China and India<\/span><\/li>\n<li class=\"ql-align-justify\"><span data-mce-mark=\"1\">List of emerging therapies with product name, company, stage of development, indication, route of administration and molecule type is also provided&nbsp;&nbsp;<\/span><\/li>\n<\/ul>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\"><span data-mce-mark=\"1\">The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university web sites and industry-specific third party sources, etc.<\/span><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\"><strong>Request for sample pages:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/acromegaly-global-api-manufacturers-marketed-and-phase-iii-drugs-landscape\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/acromegaly-global-api-manufacturers-marketed-and-phase-iii-drugs-landscape<\/a><\/strong><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\"><strong>Scope of the report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li class=\"ql-align-justify\"><span data-mce-mark=\"1\">The Acromegaly report provides a comprehensive understanding of Acromegaly marketed and emerging (Phase III) products<\/span><\/li>\n<li class=\"ql-align-justify\"><span data-mce-mark=\"1\">Access to API manufacturers details for Acromegaly marketed drugs to devise API procurement strategy for generic development<\/span><\/li>\n<li class=\"ql-align-justify\"><span data-mce-mark=\"1\">Plan developmental timelines around marketed drug patents for the major markets- US and EU<\/span><\/li>\n<li class=\"ql-align-justify\"><span data-mce-mark=\"1\">Understand current and future growth of marketed Acromegaly therapeutics through their historical and forecasted sales<\/span><\/li>\n<li class=\"ql-align-justify\"><span data-mce-mark=\"1\">Identify and analyze future sales trends of emerging Phase III Acromegaly therapeutics through their forecasted sales<\/span><\/li>\n<li class=\"ql-align-justify\"><span data-mce-mark=\"1\">Identify the products attributes and use it for target finding, drug repurposing, and precision medicine<\/span><\/li>\n<li class=\"ql-align-justify\"><span data-mce-mark=\"1\">Identify and plan ahead for prospective emerging players and their products for Acromegaly<\/span><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Table of contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">1.&nbsp;Report Introduction<\/p>\n<p style=\"text-align: justify;\"><span data-mce-mark=\"1\">2.&nbsp;<\/span><span data-mce-mark=\"1\">Acromegaly<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span data-mce-mark=\"1\">2.1.&nbsp;<\/span><span data-mce-mark=\"1\">Acromegaly<\/span><span data-mce-mark=\"1\">&nbsp;Symptoms<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span data-mce-mark=\"1\">2.2.&nbsp;<\/span><span data-mce-mark=\"1\">Acromegaly<\/span><span data-mce-mark=\"1\">&nbsp;Causes&nbsp;&nbsp;<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span data-mce-mark=\"1\">2.3.&nbsp;<\/span><span data-mce-mark=\"1\">Acromegaly&nbsp;<\/span><span data-mce-mark=\"1\">Types&nbsp;<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span data-mce-mark=\"1\">2.4.&nbsp;<\/span><span data-mce-mark=\"1\">Acromegaly<\/span><span data-mce-mark=\"1\">&nbsp;Risk Factors \/ Complications<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span data-mce-mark=\"1\">2.5.&nbsp;<\/span><span data-mce-mark=\"1\">Acromegaly<\/span><span data-mce-mark=\"1\">&nbsp;Pathophysiology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span data-mce-mark=\"1\">2.6.&nbsp;<\/span><span data-mce-mark=\"1\">Acromegaly<\/span><span data-mce-mark=\"1\">&nbsp;Diagnosis<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span data-mce-mark=\"1\">2.7.&nbsp;<\/span><span data-mce-mark=\"1\">Acromegaly<\/span><span data-mce-mark=\"1\">&nbsp;Treatment<\/span><\/p>\n<p style=\"text-align: justify;\"><span data-mce-mark=\"1\">3.<\/span><span data-mce-mark=\"1\">&nbsp;Comparative Analysis of Marketed and Emerging Products<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span data-mce-mark=\"1\">3.1. Marketed Products<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span data-mce-mark=\"1\">3.1.1.&nbsp;<\/span><span data-mce-mark=\"1\">Drug A<\/span><span data-mce-mark=\"1\">: Company&nbsp;<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span data-mce-mark=\"1\">3.1.1.1. Product Description<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span data-mce-mark=\"1\">3.1.1.2. Regulatory Milestones<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span data-mce-mark=\"1\">3.1.1.3. Product Development Activities<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span data-mce-mark=\"1\">3.1.1.3.1. General Description Table<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span data-mce-mark=\"1\">3.1.1.4. Global Sales<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span data-mce-mark=\"1\">3.1.1.5. Global API Manufacturers for Drug A<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span data-mce-mark=\"1\">3.1.1.5.1. United States<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span data-mce-mark=\"1\">3.1.1.5.2. Europe<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span data-mce-mark=\"1\">3.1.1.5.3. China&nbsp;<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span data-mce-mark=\"1\">3.1.1.5.4. India<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span data-mce-mark=\"1\">3.1.2.&nbsp;<\/span><span data-mce-mark=\"1\">Drug B<\/span><span data-mce-mark=\"1\">: Company<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span data-mce-mark=\"1\">3.1.2.1. Product Description<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span data-mce-mark=\"1\">3.1.2.2. Regulatory Milestones<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span data-mce-mark=\"1\">3.1.2.3. Product Development Activities<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span data-mce-mark=\"1\">3.1.2.3.1. General Description Table<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span data-mce-mark=\"1\">3.1.2.4. Global Sales<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span data-mce-mark=\"1\">3.1.2.5. Global API Manufacturers for Drug B<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span data-mce-mark=\"1\">3.1.2.5.1. United States<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span data-mce-mark=\"1\">3.1.2.5.2. Europe<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span data-mce-mark=\"1\">3.1.2.5.3. China&nbsp;<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span data-mce-mark=\"1\">3.1.2.5.4. India<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span data-mce-mark=\"1\">Complete details in the report<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span data-mce-mark=\"1\">3.1.3. Emerging Therapies &#8211; Late Phase&nbsp;<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span data-mce-mark=\"1\">3.1.3.1. List of Phase III drugs for&nbsp;<\/span><span data-mce-mark=\"1\">Acromegaly<\/span><\/p>\n<p style=\"text-align: justify;\"><span data-mce-mark=\"1\">4.&nbsp;<\/span><span data-mce-mark=\"1\">Appendix<\/span><\/p>\n<p style=\"text-align: justify;\"><span data-mce-mark=\"1\">5.&nbsp;<\/span><span data-mce-mark=\"1\">Report Methodology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span data-mce-mark=\"1\">5.1. Secondary Research<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span data-mce-mark=\"1\">5.2. Expert Panel Validation<\/span><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\"><strong>Download sample pages:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/acromegaly-global-api-manufacturers-marketed-and-phase-iii-drugs-landscape\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/acromegaly-global-api-manufacturers-marketed-and-phase-iii-drugs-landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<br \/><\/strong>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span><strong>Contact us:<br \/><\/strong>Shruti Thakur<br \/><span>info@delveinsight.com<\/span><br \/><span>+919650213330<\/span><\/span><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=acromegaly-global-api-manufacturers-marketed-and-phase-iii-drugs-landscape-2020-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=acromegaly-global-api-manufacturers-marketed-and-phase-iii-drugs-landscape-2020-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP &#8220;Acromegaly &#8211; Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020&#8221; report by DelveInsight offers comprehensive insights on marketed and Phase III products for Acromegaly. The marketed products information covers their product details, patents (US &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/acromegaly-global-api-manufacturers-marketed-and-phase-iii-drugs-landscape-2020-by-delveinsight_506104.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-506104","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/506104","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=506104"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/506104\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=506104"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=506104"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=506104"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}